I'm interested in news on this Bi-specific-antbody for the therapy of refractory myeloma and cut this phrase out of the Boehringer Ingelheim / Amgen report (http://bit.ly/12MG3Tw)
"To strengthen our research portfolio and expertise in developing NBEs binding to two targets (bispecific therapeutics), we have established partnerships with Ablynx NV, MacroGenics, Inc., and f-star Ges. m. b. H. Additionally, we work together with Micromet, Inc., (now part of Amgen) to develop and commercialise a BiTE® (bispecific T-cell engager) for the treatment of multiple myeloma."
Do you have informations on that item? Thank you! Thomas
|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
